Company Overview and Equity Transactions (Details)			1 Months Ended	12 Months Ended
	Mar. 26, 2021 USD ($)	Sep. 11, 2019 USD ($)	Dec. 31, 2020 USD ($) shares	Dec. 31, 2021 USD ($) product shares	Dec. 31, 2020 shares
Class of Stock [Line Items]
Number of products approved by FDA | product				5
Common Stock
Class of Stock [Line Items]
Common Stock issued upon public equity offering (in shares) | shares				6,550,486	930,933
Licensed Product
Class of Stock [Line Items]
Number of products approved by FDA | product				4
Stand Alone Product
Class of Stock [Line Items]
Number of products approved by FDA | product				1
Equity Distribution Agreement
Class of Stock [Line Items]
Sale of stock, aggregate offering price		$ 25,000,000
Number of shares issued in transaction (in shares) | shares			930,993
Consideration received on sale of stock			$ 6,055,000
Payments of stock issuance costs			$ 473,000
At The Market Offering, Amendment One | Maximum
Class of Stock [Line Items]
Sale of stock, aggregate offering price	$ 50,000,000
At The Market Offering
Class of Stock [Line Items]
Consideration received on sale of stock				$ 29,778,000
Payments of stock issuance costs				1,291,000
Remaining amount available for offering				$ 37,408,000